

Baystate Medical Center

Dear Manufacturers,

I am writing on behalf of Baystate Medical Center (BMC; 340B ID # DSH220077) to inform manufacturers that BMC recently underwent an audit by the Health Resources and Services Administration (HRSA) of BMC's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, BMC qualified for the 340B Program as a Disproportionate Share Hospital located in Springfield, Massachusetts and has participated in the 340B Program since July 1, 2003.

Through the audit process, BMC was found to have non-compliance within their 340B Program and is responsible for repayment as a result of the following finding:

BMC dispensed a 340B drug to an ineligible individual, as prohibited by 42 USC 256b (a)(5)(B). This finding was for a single prescription of thirty oral prednisone tablets at an acquisition cost of \$0.22.

BMC has identified the affected manufacturer and has contacted them to notify them of this violation and to discuss repayment. If manufacturers have not received notification from BMC and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact:

Gary J. Kerr
Chief Pharmacy Officer
Baystate Health
2 Medical Center Drive, Suite 107
Springfield, MA 01199
P 413-794-3178
F 413-794-8040